XML 52 R41.htm IDEA: XBRL DOCUMENT
v3.25.2

SEGMENT INFORMATION (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Schedule of segment revenues and profit | Segment revenues, profits and reconciliation of segment profit to consolidated Income (loss) before income taxes were as follows:
| Three Months Ended June 30,
| Salix |  | International |  | Solta Medical |  | Diversified |  | Bausch + Lomb |  | Total
(in millions) | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenues | $ | 627 |  | $ | 558 |  | $ | 278 |  | $ | 276 |  | $ | 128 |  | $ | 102 |  | $ | 219 |  | $ | 251 |  | $ | 1,278 |  | $ | 1,216 |  | $ | 2,530 |  | $ | 2,403
Less: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of goods sold (excluding amortization and impairments of intangible assets) | 39 |  | 49 |  | 117 |  | 116 |  | 36 |  | 26 |  | 33 |  | 35 |  | 523 |  | 482 |  |  |  |
Costs of other revenues | — |  | — |  | 14 |  | 10 |  | — |  | — |  | — |  | — |  | 2 |  | 1 |  |  |  |
Selling, general and administrative | 112 |  | 102 |  | 63 |  | 57 |  | 32 |  | 26 |  | 43 |  | 46 |  | 470 |  | 429 |  |  |  |
Research and development | 21 |  | 30 |  | 6 |  | 7 |  | 6 |  | 3 |  | 4 |  | 4 |  | 35 |  | 30 |  |  |  |
Segment profit | $ | 455 |  | $ | 377 |  | $ | 78 |  | $ | 86 |  | $ | 54 |  | $ | 47 |  | $ | 139 |  | $ | 166 |  | $ | 248 |  | $ | 274 |  | $ | 974 |  | $ | 950
Corporate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (261) |  |  | (254) |
Amortization of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (256) |  |  | (270) |
Asset impairments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | (5) |
Restructuring, integration and separation costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (31) |  |  | (12) |
Other (income) expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18 |  |  | (20) |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 444 |  |  | 389 |
Interest income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13 |  |  | 8 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (465) |  |  | (350) |
Gain on extinguishment of debt |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 178 |  |  | 12 |
Foreign exchange and other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (30) |  |  | (11) |
Income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 140 |  |  | $ | 48 |
| Six Months Ended June 30,
| Salix |  | International |  | Solta Medical |  | Diversified |  | Bausch + Lomb |  | Total
(in millions) | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenues | $ | 1,169 |  | $ | 1,057 |  | $ | 540 |  | $ | 541 |  | $ | 241 |  | $ | 190 |  | $ | 424 |  | $ | 453 |  | $ | 2,415 |  | $ | 2,315 |  | $ | 4,789 |  | $ | 4,556
Less: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of goods sold (excluding amortization and impairments of intangible assets) | 82 |  | 90 |  | 219 |  | 225 |  | 63 |  | 45 |  | 63 |  | 71 |  | 1,004 |  | 905 |  |  |  |
Costs of other revenues | — |  | — |  | 31 |  | 21 |  | — |  | — |  | — |  | — |  | 3 |  | 2 |  |  |  |
Selling, general and administrative | 223 |  | 204 |  | 115 |  | 110 |  | 60 |  | 51 |  | 88 |  | 94 |  | 917 |  | 834 |  |  |  |
Research and development | 38 |  | 57 |  | 12 |  | 12 |  | 11 |  | 7 |  | 7 |  | 8 |  | 63 |  | 58 |  |  |  |
Segment profit | $ | 826 |  | $ | 706 |  | $ | 163 |  | $ | 173 |  | $ | 107 |  | $ | 87 |  | $ | 266 |  | $ | 280 |  | $ | 428 |  | $ | 516 |  | $ | 1,790 |  | $ | 1,762
Corporate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (529) |  |  | (498) |
Amortization of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (512) |  |  | (544) |
Asset impairments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | (6) |
Restructuring, integration and separation costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (32) |  |  | (24) |
Other (income) expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  | (20) |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 720 |  |  | 670 |
Interest income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 24 |  |  | 17 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (795) |  |  | (705) |
Gain on extinguishment of debt |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 178 |  |  | 23 |
Foreign exchange and other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (34) |  |  | (26) |
Income (loss) before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 93 |  |  | $ | (21) |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration